Filing Flows › Connect Biopharma Holdings (CNTB) › Q4 2024
Connect Biopharma Holdings (CNTB) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Connect Biopharma Holdings (CNTB) reported revenue of $698K for the fourth quarter 2024 (Q4 2024) and -43% from the quarter before.
Connect Biopharma Holdings, Q4 2024: revenue $698K, net loss $8.9M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $698K | -43% | — |
| Operating profit | −$9.6M | — | — |
| Net earnings | −$8.9M | — | — |
| Operating cash flow | −$2.3M | — | — |
What changed
Revenue was $698K in Q4 2024, down 43% from the previous quarter.
Operating costs exceeded revenue by $9.6M, an operating margin of -1378.1%. The quarter ended with a net loss of $8.9M, narrower than the previous quarter's $12.9M loss.
Operating cash flow was −$2.3M. Non-cash charges added back $158K of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items added $5.0M. Capital expenditures of $313K exceeded it, leaving free cash flow of −$2.6M.
Questions
What was Connect Biopharma Holdings' revenue in the fourth quarter 2024?
Connect Biopharma Holdings (CNTB) reported revenue of $698K for the fourth quarter 2024 (Q4 2024) and -43% from the quarter before.